Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

18. Juni 2024 07:00 ET | Quelle: Chemomab Therapeutics

Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis

New publication confirms the role of CCL24 in primary sclerosing cholangitis and the potential of CM-101 to impact PSC disease progression and severity.
17. Juni 2024 08:44 ET | Quelle: Evaxion Biotech

Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01, in Leading Medical Journal

A 67% objective response rate (ORR) is reported in the publication summarizing results from the Phase 1 study assessing Evaxion’s personalized cancer vaccine, EVX-01, in patients with metastatic...
04. August 2014 08:30 ET | Quelle: AIM ImmunoTech Inc.

Hemispherx's Two Drugs, Ampligen(R) and Alferon(R) Ranked Highly in Sensitivity Testing Against MERS/SARS Coronaviruses

PHILADELPHIA, Aug. 4, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today a peer-reviewed electronic publication entitled "Sensitivity of SARS/MERS CoV to Interferons and...